Literature DB >> 7352017

Immune and virus-induced interferons may activate cells by different derepressional mechanisms.

F Dianzani, M Zucca, A Scupham, J A Georgiades.   

Abstract

Virus-induced interferon (VIF), and immune interferon (IIF) produced by lymphocytes following activation by various mitogens (phytohaemagglutinin, concanavalin A, staphlococcal enterotoxin A) or by specific antigenic stimulation (tuberculin, bacterial toxoids, and viral antigens) show important functional differences. These include different antitumour and immunoregulatory activities and differential inhibition of activity by mercaptoethanol. Another important difference has recently been shown: cells treated with IIF acquire the antiviral state much more slowly than those treated with VIF. This may be due to (1) difference in cellular receptors, (2) presence of an inhibitor of antiviral activity in the IIF preparations, or (3) a different mechanism of activation of the antiviral state by the two types of interferon. The first two hypotheses seem unlikely, since (1) no difference between cell association by the two types of interferon has been detected, and (2) the presence of the slow acting IIF preparation did not inhibit the rapid activation by VIF. The present study shows that the different kinetics of induction of the antiviral state result from a major difference in the mechanism by which IIF and VIF activate cells.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7352017     DOI: 10.1038/283400a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  12 in total

Review 1.  Regulation of cell growth by interferon.

Authors:  M Shearer; J Taylor-Papadimitriou
Journal:  Cancer Metastasis Rev       Date:  1987       Impact factor: 9.264

2.  A single DNA response element can confer inducibility by both alpha- and gamma-interferons.

Authors:  L E Reid; A H Brasnett; C S Gilbert; A C Porter; D R Gewert; G R Stark; I M Kerr
Journal:  Proc Natl Acad Sci U S A       Date:  1989-02       Impact factor: 11.205

3.  Synergistic antiviral and antiproliferative activities of Escherichia coli-derived human alpha, beta, and gamma interferons.

Authors:  C W Czarniecki; C W Fennie; D B Powers; D A Estell
Journal:  J Virol       Date:  1984-02       Impact factor: 5.103

4.  Interferon gamma response region in the promoter of the human DPA gene.

Authors:  Z Yang; M Sugawara; P D Ponath; L Wessendorf; J Banerji; Y Li; J L Strominger
Journal:  Proc Natl Acad Sci U S A       Date:  1990-12       Impact factor: 11.205

5.  Human interferon-gamma enhances the expression of class I and class II major histocompatibility complex products in neoplastic cells more effectively than interferon-alpha and interferon-beta.

Authors:  A Dolei; M R Capobianchi; F Ameglio
Journal:  Infect Immun       Date:  1983-04       Impact factor: 3.441

6.  Partial purification and characterization of human gamma (immune) interferon.

Authors:  Y K Yip; R H Pang; C Urban; J Vilcek
Journal:  Proc Natl Acad Sci U S A       Date:  1981-03       Impact factor: 11.205

7.  Molecular cloning of human immune interferon cDNA and its expression in eukaryotic cells.

Authors:  R Devos; H Cheroutre; Y Taya; W Degrave; H Van Heuverswyn; W Fiers
Journal:  Nucleic Acids Res       Date:  1982-04-24       Impact factor: 16.971

8.  Stimulation of human gamma interferon production by diterpene esters.

Authors:  Y K Yip; R H Pang; J D Oppenheim; M S Nachbar; D Henriksen; I Zerebeckyj-Eckhardt; J Vilcek
Journal:  Infect Immun       Date:  1981-10       Impact factor: 3.441

9.  Efficient activation of human blood monocytes to a tumoricidal state by liposomes containing human recombinant gamma interferon.

Authors:  W C Koff; W E Fogler; J Gutterman; I J Fidler
Journal:  Cancer Immunol Immunother       Date:  1985       Impact factor: 6.968

10.  Production of a monoclonal antibody directed against an interferon-induced 56,000-dalton protein and its use in the study of this protein.

Authors:  B Y Rubin; S L Anderson; R M Lunn; G R Hellermann; N K Richardson; L J Smith
Journal:  J Virol       Date:  1988-06       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.